Connor, Clark & Lunn Investment Management Ltd. Pds Biotechnology Corp Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$5.03 - $9.9 $99,166 - $195,178	-19,715 Reduced 41.49%	27,807 $139,000
Q1 2023 May 09, 2023	BUY	$5.68 - $11.99 $112,435 - $237,342	19,795 Added 71.39%	47,522 $292,000
Q4 2022 Feb 10, 2023	BUY	$3.28 - $13.2 $90,944 - $365,996	27,727 New	27,727 $365,000

Others Institutions Holding PDSB

# of Institutions

Shares Held

4.05M

Call Options Held

253K

Put Options Held

70.4K

Vanguard Group Inc Valley Forge, PA

1.52M
Shares

$2.46 Million
0.0% of portfolio
Black Rock Inc. New York, NY

487K
Shares

$788,886
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

415K
Shares

$672,483
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

234K
Shares

$379,418
0.0% of portfolio
Susquehanna International Group, LLP Bala Cynwyd, PA

134K
Shares

$217,501
0.0% of portfolio

View Full List

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $46.1M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account